Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q2 2021

Holdings as of Jun 30, 2021, filed Aug 16, 2021. Long positions only; changes compare share counts with Q1 2021.

Institution overview
Positions
28
0 vs. Q1 2021
Portfolio value
$447.2M
−$36.6M (−7.6%) vs. Q1 2021
Filed
Aug 16, 2021
SEC
Holdings of Great Point Partners LLC in Q2 2021
SecurityClassSharesValue% of portfolioShare changeActionHistory
VERVVerve Therapeutics, Inc.COM35,000$2.11M0.5%+35,000NewHistory
SYRESpyre Therapeutics, Inc.COM900,000$6.26M1.4%+397,100+79.0%AddedHistory
CTMXCytomX Therapeutics, Inc.COM1,000,000$6.33M1.4%+1,000,000NewHistory
RIGLRigel Pharmaceuticals IncCOM NEW1,500,000$6.51M1.5%+1,500,000NewHistory
IFRXInflaRx N.V.COM2,200,000$6.53M1.5%00.0%UnchangedHistory
TCDATricida, Inc.COM1,974,000$8.53M1.9%+1,624,400+464.6%AddedHistory
OLMAOlema Pharmaceuticals, Inc.COM329,086$9.21M2.1%+329,086NewHistory
ANABAnaptysbio, IncCOM400,051$10.4M2.3%+400,051NewHistory
KURAKura Oncology, Inc.COM500,000$10.4M2.3%+500,000NewHistory
DNTHDianthus Therapeutics, Inc.COM1,111,111$10.9M2.4%+1,111,111NewHistory
BIIBBiogen Inc.COM32,500$11.3M2.5%−42,500−56.7%ReducedHistory
PBYIPuma Biotechnology, Inc.COM1,300,000$11.9M2.7%00.0%UnchangedHistory
XENTIntersect ENT, Inc.COM700,000$12.0M2.7%−632,773−47.5%ReducedHistory
OCULOcular Therapeutix, IncCOM919,887$13.0M2.9%−87,125−8.7%ReducedHistory
RPTXRepare Therapeutics Inc.COM436,089$13.6M3.0%+436,089NewHistory
DYNDyne Therapeutics, Inc.COM672,559$14.2M3.2%+672,559NewHistory
SAGESage Therapeutics, Inc.COM250,000$14.2M3.2%−132,085−34.6%ReducedHistory
FOLDAmicus Therapeutics, Inc.COM1,600,000$15.4M3.4%+1,600,000NewHistory
TVTXTravere Therapeutics, Inc.COM1,084,300$15.8M3.5%+490,588+82.6%AddedHistory
MRTXMirati Therapeutics, Inc.COM100,000$16.2M3.6%−35,000−25.9%ReducedHistory
KDMNKadmon Holdings, Inc.COM4,830,000$18.7M4.2%+75,000+1.6%AddedHistory
COLLCollegium Pharmaceutical, IncCOM861,410$20.4M4.6%00.0%UnchangedHistory
EXELExelixis, Inc.COM1,394,107$25.4M5.7%+193,007+16.1%AddedHistory
PODDInsulet CorpStock104,600$28.7M6.4%+15,000+16.7%AddedHistory
UTHRUnited Therapeutics CorpCOM176,406$31.6M7.1%+20,000+12.8%AddedHistory
ARNAArena Pharmaceuticals IncCOM NEW505,670$34.5M7.7%+129,800+34.5%AddedHistory
RCKTRocket Pharmaceuticals, Inc.COM817,040$36.2M8.1%+57,040+7.5%AddedHistory
MGNXMacrogenics IncCOM1,378,495$37.0M8.3%+28,495+2.1%AddedHistory

Options (2)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Great Point Partners LLC in Q2 2021
SecurityClassPutsCalls
NTLAIntellia Therapeutics, Inc.COM–$16.2M
KYNBKyntra Bio, Inc.COM–$13.3M

Sold out since Q1 2021 (10)

Positions held at the end of Q1 2021 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q1 2021
SecurityClassShares in Q1 2021Value in Q1 2021% of portfolio in Q1 2021History
IOVAIovance Biotherapeutics, Inc.COM930,000$29.4M6.1%History
CNSTConstellation Pharmaceuticals IncCOM872,415$20.4M4.2%History
LNTHLantheus Holdings, Inc.Stock649,516$13.9M2.9%History
NVRONevro CorpCOM80,000$11.2M2.3%History
ACADAcadia Pharmaceuticals IncCOM311,217$8.03M1.7%History
LUNGPulmonx CorpCOM114,345$5.23M1.1%History
RDHLRedHill Biopharma Ltd.SPONSORED ADS705,305$5.16M1.1%History
RXDXPrometheus Biosciences, Inc.COM250,000$4.57M0.9%History
YMABY-mAbs Therapeutics, Inc.COM150,000$4.54M0.9%History
GERNGeron CorpCOM2,610,000$4.12M0.9%History